
Annovis Bio's Buntanetap Shows Promise in Reversing Cognitive Decline in Parkinson's Patients With Amyloid Co-Pathology
Annovis Bio reported new Phase 3 data showing buntanetap halted cognitive decline in Parkinson's patients and reversed deterioration in those with amyloid co-pathology, suggesting potential as a broad-acting treatment for neurodegenerative diseases.
Read full story























